Your browser doesn't support javascript.
loading
Robust and prototypical immune responses toward influenza vaccines in the high-risk group of Indigenous Australians.
Hensen, Luca; Nguyen, Thi H O; Rowntree, Louise C; Damelang, Timon; Koutsakos, Marios; Aban, Malet; Hurt, Aeron; Harland, Kim L; Auladell, Maria; van de Sandt, Carolien E; Everitt, Anngie; Blacker, Cath; Oyong, Damian A; Loughland, Jessica R; Webb, Jessica R; Wines, Bruce D; Hogarth, P Mark; Flanagan, Katie L; Plebanski, Magdalena; Wheatley, Adam; Chung, Amy W; Kent, Stephen J; Miller, Adrian; Clemens, E Bridie; Doherty, Peter C; Nelson, Jane; Davies, Jane; Tong, Steven Y C; Kedzierska, Katherine.
Afiliación
  • Hensen L; Department of Microbiology and Immunology, University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Parkville, VIC 3000, Australia.
  • Nguyen THO; Department of Microbiology and Immunology, University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Parkville, VIC 3000, Australia.
  • Rowntree LC; Department of Microbiology and Immunology, University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Parkville, VIC 3000, Australia.
  • Damelang T; Department of Microbiology and Immunology, University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Parkville, VIC 3000, Australia.
  • Koutsakos M; Department of Microbiology and Immunology, University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Parkville, VIC 3000, Australia.
  • Aban M; World Health Organization Collaborating Centre for Reference and Research on Influenza, The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.
  • Hurt A; World Health Organization Collaborating Centre for Reference and Research on Influenza, The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.
  • Harland KL; Department of Microbiology and Immunology, University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Parkville, VIC 3000, Australia.
  • Auladell M; Department of Microbiology and Immunology, University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Parkville, VIC 3000, Australia.
  • van de Sandt CE; Department of Microbiology and Immunology, University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Parkville, VIC 3000, Australia.
  • Everitt A; Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, 1066 CX Amsterdam, The Netherlands.
  • Blacker C; Menzies School of Health Research, Charles Darwin University, Darwin, NT 0810, Australia.
  • Oyong DA; Menzies School of Health Research, Charles Darwin University, Darwin, NT 0810, Australia.
  • Loughland JR; Menzies School of Health Research, Charles Darwin University, Darwin, NT 0810, Australia.
  • Webb JR; Center for Global Infectious Disease Research (CGIDR), Seattle Children's Research Institute, Seattle, WA 98109.
  • Wines BD; Menzies School of Health Research, Charles Darwin University, Darwin, NT 0810, Australia.
  • Hogarth PM; Immunology Group, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4029, Australia.
  • Flanagan KL; Menzies School of Health Research, Charles Darwin University, Darwin, NT 0810, Australia.
  • Plebanski M; Immune Therapies Laboratory, Burnet Institute, Melbourne, VIC 3084, Australia.
  • Wheatley A; Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, VIC 3010, Australia.
  • Chung AW; Department of Clinical Pathology, The University of Melbourne, Parkville, VIC 3010, Australia.
  • Kent SJ; Immune Therapies Laboratory, Burnet Institute, Melbourne, VIC 3084, Australia.
  • Miller A; Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, VIC 3010, Australia.
  • Clemens EB; Department of Clinical Pathology, The University of Melbourne, Parkville, VIC 3010, Australia.
  • Doherty PC; Tasmanian Vaccine Trial Centre, Clifford Craig Foundation, Launceston General Hospital, Launceston, TAS 7250, Australia.
  • Nelson J; School of Health Sciences and School of Medicine, University of Tasmania, Launceston, TAS 7248, Australia.
  • Davies J; Department of Immunology and Pathology, Monash University, Melbourne, VIC 3800, Australia.
  • Tong SYC; School of Health and Biomedical Science, Royal Melbourne Institute of Technology, Melbourne, VIC 3000, Australia.
  • Kedzierska K; School of Health and Biomedical Science, Royal Melbourne Institute of Technology, Melbourne, VIC 3000, Australia.
Proc Natl Acad Sci U S A ; 118(41)2021 10 12.
Article en En | MEDLINE | ID: mdl-34607957
Morbidity and mortality rates from seasonal and pandemic influenza occur disproportionately in high-risk groups, including Indigenous people globally. Although vaccination against influenza is recommended for those most at risk, studies on immune responses elicited by seasonal vaccines in Indigenous populations are largely missing, with no data available for Indigenous Australians and only one report published on antibody responses in Indigenous Canadians. We recruited 78 Indigenous and 84 non-Indigenous Australians vaccinated with the quadrivalent influenza vaccine into the Looking into InFluenza T cell immunity - Vaccination cohort study and collected blood to define baseline, early (day 7), and memory (day 28) immune responses. We performed in-depth analyses of T and B cell activation, formation of memory B cells, and antibody profiles and investigated host factors that could contribute to vaccine responses. We found activation profiles of circulating T follicular helper type-1 cells at the early stage correlated strongly with the total change in antibody titers induced by vaccination. Formation of influenza-specific hemagglutinin-binding memory B cells was significantly higher in seroconverters compared with nonseroconverters. In-depth antibody characterization revealed a reduction in immunoglobulin G3 before and after vaccination in the Indigenous Australian population, potentially linked to the increased frequency of the G3m21* allotype. Overall, our data provide evidence that Indigenous populations elicit robust, broad, and prototypical immune responses following immunization with seasonal inactivated influenza vaccines. Our work strongly supports the recommendation of influenza vaccination to protect Indigenous populations from severe seasonal influenza virus infections and their subsequent complications.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas contra la Influenza / Activación de Linfocitos / Gripe Humana / Pueblos Indígenas / Anticuerpos Antivirales Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies Límite: Humans País/Región como asunto: Oceania Idioma: En Revista: Proc Natl Acad Sci U S A Año: 2021 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas contra la Influenza / Activación de Linfocitos / Gripe Humana / Pueblos Indígenas / Anticuerpos Antivirales Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies Límite: Humans País/Región como asunto: Oceania Idioma: En Revista: Proc Natl Acad Sci U S A Año: 2021 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Estados Unidos